A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada

Allergan

Status: Withdrawn

Conditions: Uterine Fibroids

Study type: Observational

Funder types: Industry

Identifiers

NCT04567589

CMO-EPI-WH-0618

Details and patient eligibility

About

This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Healthcare Professionals (HCPs).

Full description

Data will be collected via web-based data capture by HCPs submitting surveys. The survey will be conducted in a single wave over 6 months. All data will be maintained in compliance with local regulations.

Sex

Volunteers: No Healthy Volunteers

Inclusion criteria

• HCPs have prescribed Fibristal for the indication of uterine fibroids within the past 6 months.
• HCPs have provided permission to share their responses in aggregate to Health Canada.

Exclusion criteria

• HCPs who participated in the cognitive pre-testing of the survey questionnaire to be used for the study.
• HCPs who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past 5 years.